thalidomide has been researched along with Prurigo in 60 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Prurigo: A name applied to several itchy skin eruptions of unknown cause. The characteristic course is the formation of a dome-shaped papule with a small transient vesicle on top, followed by crusting over or lichenification. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment." | 9.11 | Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004) |
| "Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age." | 9.08 | Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. ( Bielsa, I; Carrascosa, JM; Ferrándiz, C; Just, M; Ribera, M, 1997) |
| "Thalidomide has been used as an effective treatment for prurigo nodularis (PN) with a median dose of 200 mg, but the risk of peripheral neuropathy precludes long-term use." | 7.96 | An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis. ( Gupta, A; Sardana, K; Sinha, S, 2020) |
| "The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects." | 7.77 | Thalidomide in 42 patients with prurigo nodularis Hyde. ( Andersen, TP; Fogh, K, 2011) |
| "Actinic prurigo patients were analyzed before and after thalidomide treatment." | 7.72 | Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. ( Cortés-Franco, R; Domínguez-Soto, L; Estrada-G, I; Estrada-Parra, S; Flores-Romo, L; Garibay-Escobar, A; Hojyo-Tomoka, T; Núñez-Vázquez, A; Pérez-Uribe, A; Santos-Argumedo, L; Vega-Memije, E, 2004) |
| "Twenty-two patients suffering from prurigo nodularis were treated with thalidomide 50-300 mg daily for an average of 12 months (two weeks to five years), following a special arrangement between the Danish Government and the producer Grünenthal GMBH, by which the Government took full economical responsibility for any claims related to the treatment." | 7.68 | [Thalidomide treatment of prurigo nodularis]. ( Jøhnke, H; Zachariae, H, 1993) |
| "Four patients with classic recalcitrant prurigo nodularis had symptomatic and physical responses to thalidomide with remissions." | 7.67 | Thalidomide treatment of prurigo nodularis. ( Connolly, SM; Doyle, JA; Padilha-Goncalves, A; Winkelmann, RK, 1984) |
| "A 57-year-old man with prurigo nodularis, was unresponsive to conventional therapy, was successfully treated with thalidomide." | 7.66 | Treatment of prurigo nodularis with thalidomide. ( van den Broek, H, 1980) |
| "The concentration of iron, cooper and zinc in the skin of patients with prurigo nodularis was measured by diagnostic X-ray spectrometry before and after treatment with thalidomide." | 7.66 | In vivo measurements of iron, copper and zinc in the skin of prurigo nodularis patients treated with thalidomide. ( Gorodetzky, R; Loewinger, E; Sheskin, J; Weinreb, A, 1981) |
| "The literature concerning the use and possible mode of action of thalidomide in reactional lepromatous leprosy and in various other conditions is reviewed." | 7.66 | Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. ( Barnhill, RL; McDougall, AC, 1982) |
| "Fourteen patients suffering from actinic prurigo were treated with thalidomide." | 7.66 | Thalidomide in actinic prurigo. ( Calnan, CD; Hawk, JL; Lovell, CR; Magnus, IA, 1983) |
| "In the past, the regimen for treatment of prurigo nodularis often required thalidomide at 200 mg/day." | 6.73 | Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. ( Chai, CY; Chen, GS; Chen, WT; Lan, CC; Lin, CL; Wu, CS, 2007) |
| "Actinic prurigo is an uncommon and usually persistent idiopathic photodermatosis with typical human leukocyte antigen (HLA) associations (HLA-DR4, particularly subtypes DRB1*0407 and DRB1*0401)." | 6.41 | A case of severe actinic prurigo successfully treated with thalidomide. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2001) |
| "Thalidomide is an antipruritic and anti-inflammatory agent that has shown to be very effective in treating a variety of dermatologic conditions." | 5.48 | Thalidomide for the treatment of chronic refractory prurigo nodularis. ( Aguh, C; He, A; Kwatra, SG; Okoye, GA, 2018) |
| "Thalidomide is an effective treatment option in cases of recalcitrant PN; however, its most frequent adverse effect is neurotoxicity, which often results in its discontinuation." | 5.46 | Treatment of prurigo nodularis with lenalidomide. ( Arjona-Aguilera, C; Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L; Rodríguez-Mateos, ME, 2017) |
| "Actinic prurigo is a rare, often difficult-to-treat, idiopathic photodermatosis." | 5.33 | Successful thalidomide therapy for actinic prurigo in a European woman. ( Hofer, A; Holzer, A; Kerl, H; Legat, FJ; Wolf, P, 2006) |
| " This case illustrates the safe long-term use of thalidomide." | 5.31 | Long-term thalidomide for actinic prurigo. ( Muir, JB; Yong-Gee, SA, 2001) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment." | 5.11 | Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004) |
| "Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age." | 5.08 | Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. ( Bielsa, I; Carrascosa, JM; Ferrándiz, C; Just, M; Ribera, M, 1997) |
| "The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects." | 3.77 | Thalidomide in 42 patients with prurigo nodularis Hyde. ( Andersen, TP; Fogh, K, 2011) |
| "Actinic prurigo patients were analyzed before and after thalidomide treatment." | 3.72 | Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. ( Cortés-Franco, R; Domínguez-Soto, L; Estrada-G, I; Estrada-Parra, S; Flores-Romo, L; Garibay-Escobar, A; Hojyo-Tomoka, T; Núñez-Vázquez, A; Pérez-Uribe, A; Santos-Argumedo, L; Vega-Memije, E, 2004) |
| "St Vincent's Hospital Melbourne cautiously prescribes thalidomide as a treatment for recalcitrant dermatoses." | 3.71 | Thalidomide experience of a major Australian teaching hospital. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2002) |
| "We report a case of toxic pustuloderma secondary to thalidomide in a patient with severe nodular prurigo." | 3.69 | Thalidomide-induced toxic pustuloderma. ( Basarab, T; Darvay, A; Russell-Jones, R, 1997) |
| "Twenty-two patients suffering from prurigo nodularis were treated with thalidomide 50-300 mg daily for an average of 12 months (two weeks to five years), following a special arrangement between the Danish Government and the producer Grünenthal GMBH, by which the Government took full economical responsibility for any claims related to the treatment." | 3.68 | [Thalidomide treatment of prurigo nodularis]. ( Jøhnke, H; Zachariae, H, 1993) |
| "Seven patients with prurigo nodularis and one with aphthous stomatitis were given 40-115 g of thalidomide for 1 to 6 years." | 3.67 | Development of polyneuropathy during thalidomide therapy. ( Asboe-Hansen, G; Brodthagen, H; Høyer, H; Wulff, CH, 1985) |
| "Of six patients treated with thalidomide for either prurigo nodularis or discoid lupus erythematosus, four had paresthesias in the hands and feet and one also complained of muscular pain and stiffness." | 3.67 | Thalidomide neurotoxicity. ( Andersen, KE; Clemmensen, OJ; Olsen, PZ, 1984) |
| "Sensory neuropathies developed in three of four patients with prurigo nodularis who had been treated with thalidomide." | 3.67 | Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. ( Antel, J; Aronson, IK; Van den Broek, H; West, DP; Yu, R, 1984) |
| "Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug." | 3.66 | [Thalidomide in dermatology]. ( Hunziker, T; Krebs, A, 1983) |
| "The literature concerning the use and possible mode of action of thalidomide in reactional lepromatous leprosy and in various other conditions is reviewed." | 3.66 | Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. ( Barnhill, RL; McDougall, AC, 1982) |
| "Thalidomide was studied by 6 reports providing evidence of good symptom response, only 2 of which were rated level 2b or greater." | 2.61 | A systematic review of evidence-based treatments for prurigo nodularis. ( Abate, LE; Friedman, AJ; Qureshi, AA; Yosipovitch, G, 2019) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Actinic prurigo is an uncommon and usually persistent idiopathic photodermatosis with typical human leukocyte antigen (HLA) associations (HLA-DR4, particularly subtypes DRB1*0407 and DRB1*0401)." | 2.41 | A case of severe actinic prurigo successfully treated with thalidomide. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2001) |
| "Thalidomide is an antipruritic and anti-inflammatory agent that has shown to be very effective in treating a variety of dermatologic conditions." | 1.48 | Thalidomide for the treatment of chronic refractory prurigo nodularis. ( Aguh, C; He, A; Kwatra, SG; Okoye, GA, 2018) |
| "Thalidomide is an effective treatment option in cases of recalcitrant PN; however, its most frequent adverse effect is neurotoxicity, which often results in its discontinuation." | 1.46 | Treatment of prurigo nodularis with lenalidomide. ( Arjona-Aguilera, C; Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L; Rodríguez-Mateos, ME, 2017) |
| "Nodular prurigo is characterized by nodules and papules that are intensely pruritic." | 1.34 | Peripheral neuropathy associated with nodular prurigo. ( Bharati, A; Wilson, NJ, 2007) |
| "Actinic prurigo is a rare, often difficult-to-treat, idiopathic photodermatosis." | 1.33 | Successful thalidomide therapy for actinic prurigo in a European woman. ( Hofer, A; Holzer, A; Kerl, H; Legat, FJ; Wolf, P, 2006) |
| "Actinic prurigo is a specific familial photodermatosis of uncertain pathogenesis." | 1.31 | Effectors of inflammation in actinic prurigo. ( Arrese, JE; Cortés-Franco, R; Dominguez-Soto, L; Guevara, E; Hojyo-Tomoka, MT; Piérard, GE; Vega-Memije, E, 2001) |
| " This case illustrates the safe long-term use of thalidomide." | 1.31 | Long-term thalidomide for actinic prurigo. ( Muir, JB; Yong-Gee, SA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (25.00) | 18.7374 |
| 1990's | 13 (21.67) | 18.2507 |
| 2000's | 19 (31.67) | 29.6817 |
| 2010's | 8 (13.33) | 24.3611 |
| 2020's | 5 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Frølunde, AS | 1 |
| Wiis, MAK | 1 |
| Ben Abdallah, H | 1 |
| Elsgaard, S | 1 |
| Danielsen, AK | 1 |
| Deleuran, M | 1 |
| Vestergaard, C | 1 |
| Liu, T | 1 |
| Chu, Y | 1 |
| Li, S | 1 |
| Fang, H | 1 |
| Qiao, J | 1 |
| Todberg, T | 1 |
| Skov, L | 1 |
| Simonsen, S | 1 |
| Kainu, K | 1 |
| Zachariae, C | 1 |
| Arasu, A | 1 |
| Lee, S | 1 |
| Chian Yeoh, A | 1 |
| Ross, G | 1 |
| Aguh, C | 1 |
| Kwatra, SG | 1 |
| He, A | 1 |
| Okoye, GA | 1 |
| Qureshi, AA | 1 |
| Abate, LE | 1 |
| Yosipovitch, G | 1 |
| Friedman, AJ | 1 |
| Sardana, K | 1 |
| Gupta, A | 1 |
| Sinha, S | 1 |
| Liu, H | 1 |
| Gaspari, AA | 1 |
| Schleichert, R | 1 |
| Rishi, R | 1 |
| Ringwala, S | 1 |
| Tracy, J | 1 |
| Fatteh, S | 1 |
| Ossorio-García, L | 1 |
| Jiménez-Gallo, D | 1 |
| Rodríguez-Mateos, ME | 1 |
| Arjona-Aguilera, C | 1 |
| Linares-Barrios, M | 1 |
| Taefehnorooz, H | 1 |
| Truchetet, F | 1 |
| Barbaud, A | 1 |
| Schmutz, JL | 1 |
| Bursztejn, AC | 1 |
| Andersen, TP | 1 |
| Fogh, K | 1 |
| Kanavy, H | 1 |
| Bahner, J | 1 |
| Korman, NJ | 1 |
| Vega-Memije, ME | 2 |
| Mosqueda-Taylor, A | 1 |
| Irigoyen-Camacho, ME | 1 |
| Hojyo-Tomoka, MT | 3 |
| Domínguez-Soto, L | 4 |
| Crouch, RB | 2 |
| Foley, PA | 2 |
| Ng, JC | 2 |
| Baker, CS | 2 |
| Giannini, F | 1 |
| Volpi, N | 1 |
| Rossi, S | 1 |
| Passero, S | 1 |
| Fimiani, M | 1 |
| Cerase, A | 1 |
| Alfadley, A | 1 |
| Al-Hawsawi, K | 1 |
| Thestrup-Pedersen, K | 1 |
| Al-Aboud, K | 1 |
| Cortes-Franco, R | 3 |
| Maurer, T | 1 |
| Poncelet, A | 1 |
| Berger, T | 1 |
| Estrada-G, I | 1 |
| Garibay-Escobar, A | 1 |
| Núñez-Vázquez, A | 1 |
| Hojyo-Tomoka, T | 1 |
| Vega-Memije, E | 2 |
| Pérez-Uribe, A | 1 |
| Flores-Romo, L | 1 |
| Santos-Argumedo, L | 1 |
| Estrada-Parra, S | 1 |
| Ozanic Bulic, S | 1 |
| Fassihi, H | 1 |
| Mellerio, JE | 1 |
| McGrath, JA | 1 |
| Atherton, DJ | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Lee, MR | 1 |
| Shumack, S | 1 |
| Bharati, A | 1 |
| Wilson, NJ | 1 |
| Holzer, A | 1 |
| Wolf, P | 1 |
| Legat, FJ | 1 |
| Kerl, H | 1 |
| Hofer, A | 1 |
| Lan, CC | 1 |
| Lin, CL | 1 |
| Wu, CS | 1 |
| Chai, CY | 1 |
| Chen, WT | 1 |
| Chen, GS | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Stockbridge, EB | 1 |
| Deleuran, MS | 1 |
| Steiniche, T | 1 |
| Aronson, IK | 1 |
| Yu, R | 1 |
| West, DP | 1 |
| Van den Broek, H | 2 |
| Antel, J | 1 |
| Grosshans, E | 1 |
| Illy, G | 1 |
| Winkelmann, RK | 1 |
| Connolly, SM | 1 |
| Doyle, JA | 1 |
| Padilha-Goncalves, A | 1 |
| Nougué, J | 1 |
| Nougué, M | 1 |
| Bazex, J | 1 |
| Hayek, JP | 1 |
| Bidouze, H | 1 |
| Høyer, H | 2 |
| Wulff, CH | 2 |
| Asboe-Hansen, G | 2 |
| Brodthagen, H | 2 |
| Clemmensen, OJ | 1 |
| Olsen, PZ | 1 |
| Andersen, KE | 1 |
| Lovell, CR | 1 |
| Hawk, JL | 4 |
| Calnan, CD | 2 |
| Magnus, IA | 1 |
| Hunziker, T | 1 |
| Krebs, A | 1 |
| Barnhill, RL | 1 |
| McDougall, AC | 1 |
| Sheskin, J | 2 |
| Gorodetzky, R | 1 |
| Loewinger, E | 1 |
| Weinreb, A | 1 |
| Berger, TG | 1 |
| Hoffman, C | 1 |
| Thieberg, MD | 1 |
| Judge, MR | 1 |
| Kobza-Black, A | 1 |
| Bielsa, I | 2 |
| Teixidó, J | 1 |
| Ribera, M | 2 |
| Ferrándiz, C | 2 |
| Jøhnke, H | 1 |
| Zachariae, H | 1 |
| Grabczyska, SA | 1 |
| Carrascosa, JM | 1 |
| Just, M | 1 |
| Darvay, A | 1 |
| Basarab, T | 1 |
| Russell-Jones, R | 1 |
| Bronner, GM | 1 |
| Koks, CH | 1 |
| Beijnen, JH | 1 |
| Herranz, P | 1 |
| Pizarro, A | 1 |
| De Lucas, R | 1 |
| Arribas, JR | 1 |
| García-Tobaruela, A | 1 |
| Peña, JM | 1 |
| Casado, M | 1 |
| Sadoh, DR | 1 |
| Panayiotopoulos, CP | 1 |
| Rao, DG | 1 |
| Kane, NM | 1 |
| Oware, A | 1 |
| Arrese, JE | 1 |
| Guevara, E | 1 |
| Piérard, GE | 1 |
| Yong-Gee, SA | 1 |
| Muir, JB | 1 |
| Meara, RH | 1 |
| Carmichael, AJ | 1 |
| Knight, A | 1 |
| Bernal, JE | 1 |
| Duran, MM | 1 |
| Londoño, F | 1 |
| Umaña, A | 1 |
| Revuz, J | 1 |
| Naafs, B | 1 |
| Faber, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635] | Phase 3 | 159 participants (Actual) | Interventional | 2000-03-01 | Completed | ||
| A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer[NCT00001446] | Phase 2 | 64 participants | Interventional | 1995-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Thalidomide | 117 |
| Placebo | 98 |
Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Thalidomide | 15 |
| Placebo | 9.6 |
10 reviews available for thalidomide and Prurigo
| Article | Year |
|---|---|
Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
Topics: Chronic Disease; Graft vs Host Disease; Humans; Hypersensitivity, Immediate; Prurigo; Pruritus; Skin | 2022 |
A systematic review of evidence-based treatments for prurigo nodularis.
Topics: Adrenal Cortex Hormones; Anticonvulsants; Antidepressive Agents; Antipruritics; Calcineurin Inhibito | 2019 |
Treatment of prurigo nodularis with thalidomide: a case report and review of the literature.
Topics: Adult; Dermatologic Agents; Extremities; Humans; Male; Peripheral Nervous System Diseases; Prurigo; | 2003 |
Diagnosis and treatment of actinic prurigo.
Topics: Dermatologic Agents; Diagnosis, Differential; Humans; Photosensitivity Disorders; Prurigo; Thalidomi | 2003 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Prurigo nodularis: a review.
Topics: Administration, Topical; Antipruritics; Capsaicin; Cholecalciferol; Combined Modality Therapy; Cryot | 2005 |
Thalidomide therapy for inflammatory dermatoses.
Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity | 1984 |
Managing PLE and actinic prurigo.
Topics: Acute Disease; Anti-Inflammatory Agents; Humans; Immunosuppressive Agents; Photosensitivity Disorder | 1997 |
A case of severe actinic prurigo successfully treated with thalidomide.
Topics: Adult; Arm; Dermatitis, Photoallergic; Dermatologic Agents; Diagnosis, Differential; Facial Dermatos | 2001 |
[Current use of thalidomide].
Topics: Abnormalities, Drug-Induced; Behcet Syndrome; Dose-Response Relationship, Drug; Humans; Leprosy, Lep | 1990 |
4 trials available for thalidomide and Prurigo
| Article | Year |
|---|---|
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; HIV Infections; Humans; Imm | 2004 |
Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Female; Humans; Immunosuppressive Agents; Male; Middle | 2007 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.
Topics: Administration, Oral; Adult; Age Factors; Chronic Disease; Combined Modality Therapy; Female; Follow | 1997 |
46 other studies available for thalidomide and Prurigo
| Article | Year |
|---|---|
Clinical and immunological phenotype switch to prurigo nodularis in a patient receiving ixekizumab for treating psoriasis: a case report.
Topics: Antibodies, Monoclonal, Humanized; Humans; Prurigo; Psoriasis; Thalidomide | 2023 |
Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemokines; Female; Humans; Male; Middle Aged; Pilot | 2020 |
Drug survival of thalidomide for dermatological conditions: A single-centre review.
Topics: Dermatologic Agents; Humans; Prurigo; Skin Diseases; Stomatitis, Aphthous; Thalidomide | 2021 |
Thalidomide for the treatment of chronic refractory prurigo nodularis.
Topics: Administration, Topical; Aged; Biopsy; Chronic Disease; Dose-Response Relationship, Drug; Female; Ha | 2018 |
An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.
Topics: Adult; Antipruritics; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male; | 2020 |
Use of lenalidomide in treating refractory prurigo nodularis.
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Thalidomide; Treatment Outc | 2013 |
Prurigo nodularis and Hashimoto thyroiditis.
Topics: Diagnosis, Differential; Female; Hashimoto Disease; Humans; Immunologic Factors; Middle Aged; Prurig | 2014 |
Treatment of prurigo nodularis with lenalidomide.
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Remission Induction; Thalid | 2017 |
Efficacy of thalidomide in the treatment of prurigo nodularis.
Topics: Adult; Aged; Dermatologic Agents; Female; France; Humans; Male; Middle Aged; Prurigo; Retrospective | 2011 |
Thalidomide in 42 patients with prurigo nodularis Hyde.
Topics: Female; Humans; Immunosuppressive Agents; Male; Peripheral Nervous System Diseases; Prurigo; Retrosp | 2011 |
Treatment of refractory prurigo nodularis with lenalidomide.
Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Pruritus; Thalidomide; Trea | 2012 |
Actinic prurigo cheilitis: clinicopathologic analysis and therapeutic results in 116 cases.
Topics: Administration, Topical; Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anti-Inflamma | 2002 |
Thalidomide experience of a major Australian teaching hospital.
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Dermatologic Agents; Female; Humans; Lupus Erythematosus, | 2002 |
Thalidomide-induced neuropathy: a ganglionopathy?
Topics: Aged; Evoked Potentials, Somatosensory; Gait Disorders, Neurologic; Ganglia, Spinal; Humans; Magneti | 2003 |
Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo.
Topics: Adolescent; Adult; CD3 Complex; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interfe | 2004 |
Thalidomide in the management of epidermolysis bullosa pruriginosa.
Topics: Adolescent; Epidermolysis Bullosa Dystrophica; Female; Humans; Immunosuppressive Agents; Point Mutat | 2005 |
Peripheral neuropathy associated with nodular prurigo.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neural Conduction; Peripheral Nervous System Disease | 2007 |
Successful thalidomide therapy for actinic prurigo in a European woman.
Topics: Adult; Europe; Female; Humans; Photosensitivity Disorders; Prurigo; Thalidomide; Treatment Outcome | 2006 |
[Actinic prurigo].
Topics: Child; Dermatologic Agents; Female; Humans; Prurigo; Thalidomide | 2008 |
Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures.
Topics: Adult; Aged; Animals; Cells, Cultured; Female; Fetus; Ganglia, Spinal; Humans; Male; Middle Aged; Ne | 1984 |
Thalidomide treatment of prurigo nodularis.
Topics: B-Lymphocytes; Female; Humans; Immunoglobulin E; Middle Aged; Prurigo; T-Lymphocytes; Thalidomide | 1984 |
[Occurrence of a genital hemorrhage in prurigo nodularis treated with thalidomide].
Topics: Female; Humans; Metrorrhagia; Middle Aged; Prurigo; Thalidomide | 1983 |
[Treatment of prurigo nodularis Hyde with thalidomide].
Topics: Aged; Female; Humans; Male; Middle Aged; Nervous System Diseases; Prurigo; Thalidomide | 1983 |
Thalidomide neurotoxicity.
Topics: Adult; Aged; Carpal Tunnel Syndrome; Electromyography; Female; Humans; Lupus Erythematosus, Discoid; | 1984 |
Thalidomide in actinic prurigo.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Male; Midd | 1983 |
[Thalidomide in dermatology].
Topics: Animals; Female; Guinea Pigs; Humans; Immunity; Leprosy; Lupus Erythematosus, Discoid; Male; Mice; N | 1983 |
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions.
Topics: Anti-Inflammatory Agents; Chemotaxis, Leukocyte; Humans; Immunosuppressive Agents; Leprosy; Lupus Er | 1982 |
In vivo measurements of iron, copper and zinc in the skin of prurigo nodularis patients treated with thalidomide.
Topics: Adult; Copper; Female; Humans; Iron; Male; Middle Aged; Prurigo; Skin; Spectrometry, X-Ray Emission; | 1981 |
Treatment of prurigo nodularis with thalidomide.
Topics: Humans; Male; Middle Aged; Prurigo; Thalidomide | 1980 |
Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide.
Topics: Acquired Immunodeficiency Syndrome; HIV Infections; Humans; Male; Middle Aged; Photosensitivity Diso | 1995 |
Guidelines for the clinical use and dispensing of thalidomide.
Topics: Adolescent; Adult; Aged; Child; Clinical Protocols; Female; Humans; Male; Middle Aged; Photosensitiv | 1995 |
Erythroderma due to thalidomide: report of two cases.
Topics: Adult; Dermatitis, Exfoliative; Drug Eruptions; Eosinophilia; Female; Humans; Kidney Failure, Chroni | 1994 |
[Thalidomide treatment of prurigo nodularis].
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neurodermatitis; Prurigo; Thalido | 1993 |
Thalidomide-induced toxic pustuloderma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Drug Eruptions; Female; Hum | 1997 |
[Thalidomide once more in the spotlight].
Topics: Adult; Dermatologic Agents; Drug Approval; Female; HIV Wasting Syndrome; Humans; Immunosuppressive A | 1999 |
Treatment of AIDS-associated prurigo nodularis with thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dermatologic Agents; Humans; Male; Prurigo; Thalidomide | 1998 |
F-chronodispersion in patients on thalidomide.
Topics: Adolescent; Adult; Aged; Electromyography; Female; Humans; Male; Middle Aged; Muscles; Neural Conduc | 1999 |
Thalidomide neuropathy: role of F-wave monitoring.
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Neural Conduct | 2000 |
Effectors of inflammation in actinic prurigo.
Topics: Adolescent; Adult; Child; Female; Genetic Predisposition to Disease; Humans; Immunohistochemistry; I | 2001 |
Long-term thalidomide for actinic prurigo.
Topics: Adult; HLA-DR4 Antigen; Humans; Immunosuppressive Agents; Male; Photosensitivity Disorders; Prurigo; | 2001 |
Actinic prurigo (Hutchinson's summer prurigo).
Topics: Adult; Diagnosis, Differential; Female; Humans; Male; Photosensitivity Disorders; Prurigo; Seasons; | 1977 |
[Treatment of prurigo nodularis Hyde using thalidomide].
Topics: Eczema; Female; Humans; Middle Aged; Prurigo; Syndrome; Thalidomide | 1975 |
Thalidomide: a restricted role.
Topics: Female; Humans; Middle Aged; Prurigo; Sunlight; Thalidomide | 1992 |
Cellular immune effects of thalidomide in actinic prurigo.
Topics: CD4-CD8 Ratio; Female; Humans; Male; Prurigo; Thalidomide; Ultraviolet Rays | 1992 |
Thalidomide therapy. An open trial.
Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu | 1985 |
Development of polyneuropathy during thalidomide therapy.
Topics: Action Potentials; Adult; Aged; Female; Humans; Leg; Male; Middle Aged; Neural Conduction; Neurons, | 1985 |